About Us
Sunridge International is a publicly traded company dedicated to revolutionizing glaucoma treatment through the global expansion of Pneumatic Trabeculoplasty (PNT). Our mission is to provide a safe, effective, and non-invasive solution for glaucoma patients while improving access to advanced care worldwide. As we grow, we remain committed to giving back to those in need, ensuring that our innovations benefit communities regardless of financial or geographical barriers. Through strategic partnerships and cutting-edge medical advancements, Sunridge International is shaping the future of glaucoma treatment.
Ophthalmic International, a wholly owned subsidiary of Sunridge International, developed and patented Pneumatic Trabeculoplasty (PNT). We have obtained CE marking and regulatory approvals throughout the world, while conducting extensive clinical studies and research to validate PNT’s safety and effectiveness. As the exclusive manufacturer and supplier of PNT equipment, we are committed to expanding access to this proven technology globally.
Management Team
G. Richard Smith, Chairman
​Richard Smith is the founder of Sunridge International and its wholly owned subsidiary, Ophthalmic International. With over 40 years of experience in developing, manufacturing, and distributing innovative ophthalmic products, he has consistently driven progress in the field. In the 1980s, he expanded an ophthalmic microscope company into the fields of neurology and coposcopy, while also developing and patenting equipment for MKM In-situ (Myopic Keratomileusis), demonstrating his ability to lead innovation across multiple medical specialties.
Through Ophthalmic International, Mr. Smith developed and patented PNT, secured CE marking, ISO certification, and 2A European Approval. He established an international market for the procedure while also leading clinical studies and regulatory efforts across multiple countries—including early steps toward FDA approval. Under his leadership, Sunridge International remains committed to expanding global access to safe, effective, and non-invasive glaucoma treatment.
Victor Webb, Director
Victor Webb is a renowned pioneer in International Investor Relations. A journalist by training, he has worked for and contributed to several international publications and held key executive roles at Dow Jones, including Managing Director of Dow Jones International Marketing Services and International Director of Dow Jones & Co., Inc.
As Vice President of the Dow Jones International Group, he was responsible for worldwide advertising and marketing for major publications such as The Wall Street Journal and Barron’s. He played a pivotal role in establishing the Asian and European editions of The Wall Street Journal.
After leaving Dow Jones, Mr. Webb successfully built Marston Webb International into a premier IR agency, serving a diverse clientele across the mining, biotech, alternative energy, manufacturing, and government sectors.
John W. Sharkey, Ph.D., Director
John W. Sharkey is a seasoned executive with over 30 years of experience in the pharmaceutical and medical device industries, specializing in business development, regulatory affairs, and manufacturing operations. He has played a key role in the development, acquisition, and commercialization of multiple products, with revenues ranging from $5 million to over $2 billion. A skilled negotiator, he has successfully structured and executed transformational deals that have propelled companies into new therapeutic areas, including oncology and infectious diseases.
Currently serving as Vice President of Business Development at GeoVax, Dr. Sharkey has been instrumental in advancing the company’s vaccine and immunotherapy programs. His leadership has extended across executive roles at Novartis, Shionogi, Largent Health, and his own firm, Cogas Consulting, where he has guided companies through product development, regulatory approvals, and strategic financing.